Last reviewed · How we verify
Gabapentin Treatment of Benzodiazepine Dependence
Benzodiazepine dependence is a growing public health problem for which very few evidenced-based treatment approaches are available. Approximately 683,000 individuals met past year criteria for sedative-hypnotic use disorders in the US during 2010, a prevalence greater than heroin or methamphetamine dependence. The most commonly prescribed sedative-hypnotic agents are the benzodiazepines. Chronic use induces pharmacodynamic tolerance in the GABA neurotransmitter system and individuals with physiological dependence find benzodiazepines difficult to discontinue because of withdrawal or rebound symptoms, which include autonomic arousal, depression, anxiety, and insomnia. Available evidence-based treatment approaches have been primarily directed at therapeutic users of benzodiazepines who do not meet criteria for a substance use disorder, with a general consensus that the gradual taper of benzodiazepines over a period of several months is the optimal approach. However, patients with benzodiazepine dependence are typically referred for inpatient detoxification treatment, which rapidly tapers patients off benzodiazepines. Protracted withdrawal symptoms frequently persist after discharge, predisposing patients to relapse. More effective pharmacotherapeutic strategies are needed for the treatment of benzodiazepine dependence in the outpatient setting.
Details
| Lead sponsor | New York State Psychiatric Institute |
|---|---|
| Phase | Phase 2 |
| Status | TERMINATED |
| Enrolment | 2 |
| Start date | 2013-07 |
| Completion | 2016-04-01 |
Conditions
- Benzodiazepine Dependence
Interventions
- gabapentin
- Placebo
Primary outcomes
- Abstinence From Benzodiazepine Use — last two weeks of 12 week trial
Achievement of two weeks abstinence from benzodiazepine use at end of trial
Countries
United States